Search

Your search keyword '"Tiseo M."' showing total 13 results
Start Over Author "Tiseo M." Journal lung cancer
13 results on '"Tiseo M."'

2. PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC)

Author

Cavazzoni, A., primary, Digiacomo, G., additional, Volta, F., additional, Alfieri, R., additional, Giovannetti, E., additional, Gnetti, L., additional, Bellini, L., additional, Galetti, M., additional, Fumarola, C., additional, Xu, G., additional, Bonelli, M., additional, La Monica, S., additional, Verzè, M., additional, Leonetti, A., additional, Eltayeb, K., additional, D'Agnelli, S., additional, Moron Dalla Tor, L., additional, Minari, R., additional, Petronini, P.G., additional, and Tiseo, M., additional

Published
2023
Full Text
View/download PDF

3. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Author

Mazzaschi, G., primary, Minari, R., additional, Zecca, A., additional, Cavazzoni, A., additional, Ferri, V., additional, Mori, C., additional, Squadrilli, A., additional, Bordi, P., additional, Buti, S., additional, Bersanelli, M., additional, Leonetti, A., additional, Cosenza, A, additional, Ferri, L., additional, Rapacchi, E., additional, Missale, G., additional, Petronini, P.G., additional, Quaini, F., additional, and Tiseo, M, additional

Published
2020
Full Text
View/download PDF

4. Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial

Author

Califano, R., primary, Camidge, D., additional, Kim, H.-R., additional, Ahn, M.-J., additional, Yang, J., additional, Han, J.-Y., additional, Hochmair, M., additional, Lee, K.H., additional, Delmonte, A., additional, Campelo, M.R. Garcia, additional, Kim, D.-W., additional, Griesinger, F., additional, Felip, E., additional, Spira, A., additional, Gettinger, S., additional, Tiseo, M., additional, Ni, Q., additional, Zhang, P., additional, and Popat, S., additional

Published
2020
Full Text
View/download PDF

5. Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial

Author

Kim, D., primary, Huber, R., additional, Ahn, M., additional, Langer, C., additional, Tiseo, M., additional, West, H., additional, Groen, H., additional, Reckamp, K., additional, Hochmair, M., additional, Leighl, N., additional, Hansen, K.H., additional, Gettinger, S., additional, Paz-Ares Rodriguez, L., additional, Kim, E., additional, Smit, E., additional, Kim, S., additional, Reichmann, W., additional, Kerstein, D., additional, and Camidge, D.R., additional

Published
2019
Full Text
View/download PDF

6. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

Author

Minari, R., primary, Bordi, P., additional, Del Re, M., additional, Facchinetti, F., additional, Mazzoni, F., additional, Barbieri, F., additional, Camerini, A., additional, Comin, C.E., additional, Gnetti, L., additional, Azzoni, C., additional, Nizzoli, R., additional, Bortesi, B., additional, Rofi, E., additional, Petreni, P., additional, Campanini, N., additional, Rossi, G., additional, Danesi, R., additional, and Tiseo, M., additional

Published
2018
Full Text
View/download PDF

8. Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey

Author

Zucali, P.A., primary, Simonelli, M., additional, Michetti, G., additional, Tiseo, M., additional, Ceresoli, G.L., additional, Collovà, E., additional, Follador, A., additional, Lo Dico, M., additional, Moretti, A., additional, De Vincenzo, F., additional, Lorenzi, E., additional, Perrino, M., additional, Giordano, L., additional, Farina, G., additional, Santoro, A., additional, and Garassino, M., additional

Published
2012
Full Text
View/download PDF

12. P-584 Single agent gemcitabine (GEM) in performance status (PS) 2–3patients (pts) with advanced non-small cell lung cancer (NSCLC): Effect on disease-related symptoms in a multicenter phase II trial

Author

Tiseo, M., primary, Tognoni, A., additional, Carob, C., additional, Mencoboni, M., additional, Pennucci, M., additional, Coialbu, T., additional, Brema, F., additional, Grossi, F., additional, Pronzato, P., additional, and Ardizzoni, A., additional

Published
2005
Full Text
View/download PDF

13. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

Author

Vittorio Franciosi, Marzia Capelletti, Nicoletta Campanini, Guido Rindi, Alessandro Marchioni, Elena Spiritelli, Giulio Rossi, Cecilia Bozzetti, Roberta Camisa, Giuseppe De Palma, Costanza Lagrasta, Andrea Ardizzoni, Luca Boni, Giuliana Sartori, Marcello Tiseo, Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, and Ardizzoni A

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Receptor, ErbB-2, Gene Dosage, non-small cell lung cancer (NSCLC), Antineoplastic Agents, NSCLC Gefitinib EGFR gene mutation EGFR FISH EGFR gene polymorphism Biological predictive factors, Gene mutation, EGFR Gene Mutation, Gene dosage, Gefitinib, Carcinoma, Non-Small-Cell Lung, Internal medicine, Biomarkers, Tumor, medicine, Carcinoma, Humans, Prospective Studies, Epidermal growth factor receptor, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Polymorphism, Genetic, biology, business.industry, Cancer, Middle Aged, Prognosis, medicine.disease, Introns, respiratory tract diseases, ErbB Receptors, Treatment Outcome, Immunology, Quinazolines, biology.protein, Female, business, medicine.drug
Abstract

A number of different clinical characteristics and molecular markers related to epidermal growth factor receptor (EGFR) activation have been reported to singly correlate with therapeutic activity of EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). This study was designed to evaluate the predictive value on gefitinib outcomes of a comprehensive panel of molecular parameters in advanced NSCLC patients EGFR and K-ras mutations were detected by direct sequencing on tumor DNA from paraffin embedded samples EGFR and HER2 gene copy number was assessed by FISH EGFR protein expression was quantified by immunohistochemistry. EGFR gene intron 1 polymorphism was assessed on genomic DNA isolated from venous whole blood samples Ninety-one patients were prospectively enrolled and the overall gefitinib response rate was 18 7% (2 complete and 15 partial responses) Sex (p = 0005), non-smoking status (p = 0010). skin toxicity (p = 0020). EGFR gene mutations (p

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results